BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37651560)

  • 21. The local cytokine and growth factor response to recombinant human bone morphogenetic protein-2 (rhBMP-2) after spinal fusion.
    Koerner JD; Markova DZ; Schroeder GD; Calio BP; Shah A; Brooks CW; Vaccaro AR; Anderson DG; Kepler CK
    Spine J; 2018 Aug; 18(8):1424-1433. PubMed ID: 29550606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial.
    Dawson E; Bae HW; Burkus JK; Stambough JL; Glassman SD
    J Bone Joint Surg Am; 2009 Jul; 91(7):1604-13. PubMed ID: 19571082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
    Haid RW; Branch CL; Alexander JT; Burkus JK
    Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
    Barnes B; Boden SD; Louis-Ugbo J; Tomak PR; Park JS; Park MS; Minamide A
    Spine (Phila Pa 1976); 2005 May; 30(10):1127-33. PubMed ID: 15897825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is lumbar facet fusion biomechanically equivalent to lumbar posterolateral onlay fusion?
    Toth JM; Foley KT; Wang M; Seim HB; Simon Turner A
    J Neurosurg Spine; 2017 May; 26(5):586-593. PubMed ID: 28156207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repeat use of human recombinant bone morphogenetic protein-2 for second level lumbar arthrodesis.
    Singh K; Dumonski M; Stanley T; Ponnappan R; Phillips FM
    Spine (Phila Pa 1976); 2011 Feb; 36(3):192-6. PubMed ID: 20634780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone Regeneration by Controlled Release of Bone Morphogenetic Protein-2: A Rabbit Spinal Fusion Chamber Molecular Study.
    Hu T; Naidu M; Yang Z; Lam WM; Kumarsing RA; Ren X; Ng F; Wang M; Liu L; Tan KC; Kwok KT; Goodman SB; Goh JC; Wong HK
    Tissue Eng Part A; 2019 Oct; 25(19-20):1356-1368. PubMed ID: 30727849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of bone morphogenetic protein and basic fibroblast growth factor on cultured mesenchymal stem cells for spine fusion.
    Minamide A; Yoshida M; Kawakami M; Okada M; Enyo Y; Hashizume H; Boden SD
    Spine (Phila Pa 1976); 2007 May; 32(10):1067-71. PubMed ID: 17471086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of recombinant human bone morphogenetic protein-2 with local bone graft instead of iliac crest bone graft in posterolateral lumbar spine arthrodesis.
    Park DK; Kim SS; Thakur N; Boden SD
    Spine (Phila Pa 1976); 2013 May; 38(12):E738-47. PubMed ID: 23474598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
    Crawford CH; Carreon LY; McGinnis MD; Campbell MJ; Glassman SD
    Spine (Phila Pa 1976); 2009 Jun; 34(13):1390-4. PubMed ID: 19440166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of carriers of bone morphogenetic protein for spinal fusion.
    Minamide A; Kawakami M; Hashizume H; Sakata R; Tamaki T
    Spine (Phila Pa 1976); 2001 Apr; 26(8):933-9. PubMed ID: 11317116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model.
    Fischgrund JS; James SB; Chabot MC; Hankin R; Herkowitz HN; Wozney JM; Shirkhoda A
    J Spinal Disord; 1997 Dec; 10(6):467-72. PubMed ID: 9438810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
    Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
    Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the osteogenesis and fusion rates between activin A/BMP-2 chimera (AB204) and rhBMP-2 in a beagle's posterolateral lumbar spine model.
    Zheng GB; Yoon BH; Lee JH
    Spine J; 2017 Oct; 17(10):1529-1536. PubMed ID: 28522401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age.
    Glassman SD; Carreon LY; Djurasovic M; Campbell MJ; Puno RM; Johnson JR; Dimar JR
    Spine (Phila Pa 1976); 2008 Dec; 33(26):2843-9. PubMed ID: 19092613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of platelet-rich plasma and bone marrow on murine posterolateral lumbar spine arthrodesis with bone morphogenetic protein.
    Rao RD; Gourab K; Bagaria VB; Shidham VB; Metkar U; Cooley BC
    J Bone Joint Surg Am; 2009 May; 91(5):1199-206. PubMed ID: 19411469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats.
    Wang JC; Kanim LE; Yoo S; Campbell PA; Berk AJ; Lieberman JR
    J Bone Joint Surg Am; 2003 May; 85(5):905-11. PubMed ID: 12728043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effects of High-Dose Parathyroid Hormone Treatment on Fusion Outcomes in a Rabbit Model of Posterolateral Lumbar Spinal Fusion Alone and in Combination with Bone Morphogenetic Protein 2 Treatment.
    Holmes CA; Ishida W; Elder BD; Lo SL; Chen YA; Kim E; Locke J; Taylor M; Witham TF
    World Neurosurg; 2018 Jul; 115():e366-e374. PubMed ID: 29678698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model.
    Namikawa T; Terai H; Hoshino M; Kato M; Toyoda H; Yano K; Nakamura H; Takaoka K
    Spine (Phila Pa 1976); 2007 Oct; 32(21):2294-9. PubMed ID: 17906568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
    Boden SD; Kang J; Sandhu H; Heller JG
    Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.